These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36558023)

  • 1. Rapid Detection of Recurrent Non-Muscle Invasive Bladder Cancer in Urine Using ATR-FTIR Technology.
    El-Falouji AI; Sabri DM; Lotfi NM; Medany DM; Mohamed SA; Alaa-Eldin M; Selim AM; El Leithy AA; Kalil H; El-Tobgy A; Mohamed A
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36558023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder cancer diagnosis from bladder wash by Fourier transform infrared spectroscopy as a novel test for tumor recurrence.
    Gok S; Aydin OZ; Sural YS; Zorlu F; Bayol U; Severcan F
    J Biophotonics; 2016 Sep; 9(9):967-75. PubMed ID: 27041149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Miyake M; Nishimura N; Nishioka Y; Fujii T; Oda Y; Miyamoto T; Tomizawa M; Shimizu T; Owari T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Imamura T; Fujimoto K
    Int Urol Nephrol; 2024 Mar; 56(3):827-837. PubMed ID: 37910382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
    Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
    World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
    Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of urine cytology as a routine work-up in the detection of recurrence in patients with prior non-muscle-invasive bladder cancer: practicality and cost-effectiveness.
    Ok BG; Ji YS; Ko YH; Song PH
    Korean J Urol; 2014 Oct; 55(10):650-5. PubMed ID: 25324947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.
    Hurle R; Casale P; Saita A; Colombo P; Elefante GM; Lughezzani G; Fasulo V; Paciotti M; Domanico L; Bevilacqua G; Maffei D; Diana P; Frego N; Sandri MT; Maura F; Morenghi E; Buffi NM; Guazzoni G; Lazzeri M
    World J Urol; 2020 Sep; 38(9):2215-2220. PubMed ID: 31691083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
    Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
    J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer.
    Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H
    Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
    Hekman MCH; Wijn SRW; Lotan Y; Govers TM; Witjes JA
    World J Urol; 2023 Feb; 41(2):471-476. PubMed ID: 36534153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTIR spectroscopy of biofluids revisited: an automated approach to spectral biomarker identification.
    Ollesch J; Drees SL; Heise HM; Behrens T; Brüning T; Gerwert K
    Analyst; 2013 Jul; 138(14):4092-102. PubMed ID: 23712384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR) Spectroscopy Discriminates the Elderly with a Low and High Percentage of Pathogenic CD4+ T Cells.
    Praja RK; Wongwattanakul M; Tippayawat P; Phoksawat W; Jumnainsong A; Sornkayasit K; Leelayuwat C
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative predictive factors of carcinoma in situ in the normal-appearing mucosa in patients who underwent an initial transurethral resection for non-muscle-invasive bladder cancer under white light cystoscopy.
    Iinuma K; Yuhara K; Kotaka H; Ozawa K; Kato D; Takai M; Nakane K; Mizutani K; Tsuchiya T; Koie T
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1321. PubMed ID: 33174397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
    Sörenby A; Baseckas G; Bendahl PO; Brändstedt J; Håkansson U; Nilsson S; Patschan O; Tinzl M; Wokander M; Liedberg F; Gudjonsson S
    Scand J Urol; 2019; 53(2-3):109-115. PubMed ID: 31064253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.